GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » EV-to-EBITDA

BioLight Life Sciences (BioLight Life Sciences) EV-to-EBITDA : -37.92 (As of Apr. 26, 2024)


View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioLight Life Sciences's enterprise value is $267.91 Mil. BioLight Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.07 Mil. Therefore, BioLight Life Sciences's EV-to-EBITDA for today is -37.92.

The historical rank and industry rank for BioLight Life Sciences's EV-to-EBITDA or its related term are showing as below:

BOLT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.98   Med: -0.57   Max: 1.51
Current: -0.27

During the past 12 years, the highest EV-to-EBITDA of BioLight Life Sciences was 1.51. The lowest was -17.98. And the median was -0.57.

BOLT's EV-to-EBITDA is ranked worse than
100% of 473 companies
in the Biotechnology industry
Industry Median: 9.22 vs BOLT: -0.27

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), BioLight Life Sciences's stock price is $32.60. BioLight Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, BioLight Life Sciences's PE Ratio (TTM) for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


BioLight Life Sciences EV-to-EBITDA Historical Data

The historical data trend for BioLight Life Sciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences EV-to-EBITDA Chart

BioLight Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.16 1.03 -15.44 -1.70 -0.60

BioLight Life Sciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.44 4.90 -1.70 - -0.60

Competitive Comparison of BioLight Life Sciences's EV-to-EBITDA

For the Biotechnology subindustry, BioLight Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLight Life Sciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's EV-to-EBITDA falls into.



BioLight Life Sciences EV-to-EBITDA Calculation

BioLight Life Sciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=267.911/-7.065
=-37.92

BioLight Life Sciences's current Enterprise Value is $267.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences  (NAS:BOLT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioLight Life Sciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=32.60/0.000
=N/A

BioLight Life Sciences's share price for today is $32.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioLight Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


BioLight Life Sciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLight Life Sciences (BioLight Life Sciences) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101
BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.